Drug intelligence / Profile preview

HKP106

Development stage: Preclinical
Lead developer: Hankook Korus Pharm
Modality: Recombinant Proteins and Enzymes

Overview

HKP106 is a recombinant protein version of Epidermal Growth Factor (EGF) currently under development by Hankook Korus Pharm. It functions as an agonist for the Epidermal Growth Factor Receptor (EGFR), which triggers signaling pathways that stimulate the proliferation, differentiation, and migration of epithelial cells. This biological activity is leveraged to accelerate the natural wound healing process and tissue regeneration. The program is currently in the preclinical stage, specifically focusing on process development for therapeutic applications in epidermal repair.

Other names: Epidermal Growth FactorEGF

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on HKP106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HKP106.

Explore the full profile